Biopharma VC Funding in Q2 Reaches Highest Quarterly Level Since 2022

Venture capital in the sector hit $9.2 billion in the second quarter of 2024, up from $7.4 billion in Q1, while exits fell on a slower M&A cycle and picky IPO market.

Scroll to Top